Research across kidney, bladder, and prostate cancers was showcased January 25-27 in San Francisco, California.
The Genitourinary Cancers Symposium took place Thursday, January 25, 2024, to Saturday, January 27, 2024, in San Francisco, California. Posters and presentations revealed the latest updates across kidney, bladder, and prostate cancer research.
Immunotherapy took center stage, with findings from the phase 3 AMBASSADOR Alliance A031501 (NCT03244384) and KEYNOTE-564 (NCT03142334) trials. Findings from a phase 2 trial (NCT03012321) of olaparib (Lynparza) plus abiraterone (Zytiga) and prednisone in metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM alterations were also highly anticipated.
Here are some of the highlights from the 3-day event.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More